Product Description
Uracil is a common and naturally occurring pyrimidine nucleobase in which the pyrimidine ring is substituted with two oxo groups at positions 2 and 4. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/URACIL)
Mechanisms of Action: P1 Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Brazil | Chile | Colombia | Dominican Republic | Germany | Hong Kong | India | Ireland | Malaysia | Mexico | Morocco | New Zealand | Pakistan | Peru | Philippines | Russia | Spain | Taiwan | Thailand | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Taiko Co
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Colorectal Cancer
Phase 3: Colorectal Cancer|Gastrointestinal Cancer|Anal Cancer|Breast Cancer|Adenocarcinoma|Bladder Cancer|Squamous Cell Carcinoma|Head and Neck Cancer|Nasopharyngeal Cancer
Phase 2: Squamous Cell Carcinoma|Head and Neck Cancer|Hepatocellular Carcinoma|Gastrointestinal Cancer|Hand-Foot Syndrome|Breast Cancer|Esophageal Cancer|Colorectal Cancer|Gastroparesis
Phase 1: Gastroparesis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 23228/ESCC-Chemo | N/A |
Recruiting |
Squamous Cell Carcinoma|Esophageal Cancer |
2025-12-31 |
|
| TPFmORL | P2 |
Active, not recruiting |
Head and Neck Cancer |
2025-06-01 |
|
| URACILMPACT | N/A |
Completed |
Dihydropyrimidine Dehydrogenase Deficiency |
2021-02-10 |
|
| 103-0621A3 | P2 |
Unknown status |
Squamous Cell Carcinoma |
2020-05-11 |